BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 12576461)

  • 1. Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity.
    Tortora G; Caputo R; Damiano V; Caputo R; Troiani T; Veneziani BM; De Placido S; Bianco AR; Zangemeister-Wittke U; Ciardiello F
    Clin Cancer Res; 2003 Feb; 9(2):866-71. PubMed ID: 12576461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenic activity.
    Tortora G; Caputo R; Damiano V; Fontanini G; Melisi D; Veneziani BM; Zunino F; Bianco AR; Ciardiello F
    Clin Cancer Res; 2001 Dec; 7(12):4156-63. PubMed ID: 11751516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.
    Tortora G; Caputo R; Damiano V; Melisi D; Bianco R; Fontanini G; Veneziani BM; De Placido S; Bianco AR; Ciardiello F
    Clin Cancer Res; 2003 Apr; 9(4):1566-72. PubMed ID: 12684433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa).
    Bianco C; Tortora G; Bianco R; Caputo R; Veneziani BM; Caputo R; Damiano V; Troiani T; Fontanini G; Raben D; Pepe S; Bianco AR; Ciardiello F
    Clin Cancer Res; 2002 Oct; 8(10):3250-8. PubMed ID: 12374696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
    Ciardiello F; Caputo R; Bianco R; Damiano V; Fontanini G; Cuccato S; De Placido S; Bianco AR; Tortora G
    Clin Cancer Res; 2001 May; 7(5):1459-65. PubMed ID: 11350918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide.
    Bianco C; Bianco R; Tortora G; Damiano V; Guerrieri P; Montemaggi P; Mendelsohn J; De Placido S; Bianco AR; Ciardiello F
    Clin Cancer Res; 2000 Nov; 6(11):4343-50. PubMed ID: 11106252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined blockade of protein kinase A and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis.
    Tortora G; Caputo R; Damiano V; Bianco R; Fontanini G; Cuccato S; De Placido S; Bianco AR; Ciardiello F
    Clin Cancer Res; 2001 Aug; 7(8):2537-44. PubMed ID: 11489837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.
    Ciardiello F; Bianco R; Damiano V; Fontanini G; Caputo R; Pomatico G; De Placido S; Bianco AR; Mendelsohn J; Tortora G
    Clin Cancer Res; 2000 Sep; 6(9):3739-47. PubMed ID: 10999768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
    Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; De Placido S; Bianco AR; Tortora G
    Clin Cancer Res; 2000 May; 6(5):2053-63. PubMed ID: 10815932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors.
    Damiano V; Caputo R; Bianco R; D'Armiento FP; Leonardi A; De Placido S; Bianco AR; Agrawal S; Ciardiello F; Tortora G
    Clin Cancer Res; 2006 Jan; 12(2):577-83. PubMed ID: 16428503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
    Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antisense targeting protein kinase A type I as a drug for integrated strategies of cancer therapy.
    Tortora G; Ciardiello F
    Ann N Y Acad Sci; 2003 Dec; 1002():236-43. PubMed ID: 14751838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.
    Janmaat ML; Kruyt FA; Rodriguez JA; Giaccone G
    Clin Cancer Res; 2003 Jun; 9(6):2316-26. PubMed ID: 12796401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast.
    Chan KC; Knox WF; Gee JM; Morris J; Nicholson RI; Potten CS; Bundred NJ
    Cancer Res; 2002 Jan; 62(1):122-8. PubMed ID: 11782368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CpG immunomer DNA enhances antisense protein kinase A RIalpha inhibition of multidrug-resistant colon carcinoma growth in nude mice: molecular basis for combinatorial therapy.
    Nesterova MV; Johnson NR; Stewart T; Abrams S; Cho-Chung YS
    Clin Cancer Res; 2005 Aug; 11(16):5950-5. PubMed ID: 16115938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
    Sirotnak FM; Zakowski MF; Miller VA; Scher HI; Kris MG
    Clin Cancer Res; 2000 Dec; 6(12):4885-92. PubMed ID: 11156248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa).
    Huang SM; Li J; Armstrong EA; Harari PM
    Cancer Res; 2002 Aug; 62(15):4300-6. PubMed ID: 12154033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti-epidermal growth factor-receptor antibody on human breast cancer cell growth.
    Tortora G; Caputo R; Pomatico G; Pepe S; Bianco AR; Agrawal S; Mendelsohn J; Ciardiello F
    Clin Cancer Res; 1999 Apr; 5(4):875-81. PubMed ID: 10213224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced antiangiogenic therapy of squamous cell carcinoma by combined endostatin and epidermal growth factor receptor-antisense therapy.
    Li M; Ye C; Feng C; Riedel F; Liu X; Zeng Q; Grandis JR
    Clin Cancer Res; 2002 Nov; 8(11):3570-8. PubMed ID: 12429648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.